$Zai Lab (ZLAB.US)$ Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has received Orphan Drug Designation (ODD) from the U.S. FDA for ZL-1310, their first-in-class DLL3 antibody-drug conjugate (ADC) designed to treat small cell lung cancer (SCLC). The designation comes after promising results from an ongoing Phase 1a/1b study in patients with previously treated extensive-stage SCL...
Zai Lab's share price drops despite revenue growth, hinting at profitability issues. The company may need to raise capital soon. Shareholders have faced an annual loss of 8% over the past five years.
102205701
:
$WAN KEI GROUP(01718.HK)$ One of the victims of recent scamming scheme by “Mr. Luke”. Blame myself for being too blinded by greed. But I am gonna share my personal experience, hopefully this will reach out to many more people for better awareness. I pray that no one be scammed by this kind of bastards again. Here is how the scamming scheme goes. I was added into Futu Securities whatsapp group soon after I opened the MooMoo account. He suggested some HK stocks to buy at a specific price and then when to sell off. Made a few bucks here and there for about 2-3 transactions (about 4months). About the time that he gained your trust, he will start his actual scamming scheme, telling you that you will make 30% or more profit for his suggested stock within 3-7days. Also suggest to invest huge amount like $150K-1M or more and then he will add you to his super VVIP group. So I did buy this Wan Kei stock at $2.8. And the next day, it was pumped to $0.8. There goes the hard earned money disappeared in a blink. This incident is a hard slap in my face. On the other hand, I am starting to doubt the data security of MooMoo. Futu Securities is MooMoo’s parent company. Is this scamming scheme actually behind by Futu? Or our user data in MooMoo system are being leaked to this scammers especially of the newbie’s profile? I hope others will start sharing more of their personal experience for other people from becoming the victims.
Market expectations suggest a decline in Zai Lab's future revenue, possibly suppressing the P/S. Investors appear to anticipate limited growth, paying less for the stock. These conditions may continue to hinder the share price.
Zai Lab Stock Forum
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has received Orphan Drug Designation (ODD) from the U.S. FDA for ZL-1310, their first-in-class DLL3 antibody-drug conjugate (ADC) designed to treat small cell lung cancer (SCLC). The designation comes after promising results from an ongoing Phase 1a/1b study in patients with previously treated extensive-stage SCL...
No comment yet